ATC codes:
A02BA02
EMLc
Indication
Peptic ulcer, site unspecified
ICD11 code:
DA61
INN
Ranitidine
Medicine type
Chemical agent
List type
Core
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Liquid:
75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
EML status history
Sex
All
Age
Also recommended for children
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
Therapeutic alternatives limitations for EMLc
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.